Astrin Biosciences

Pre-clinical

San Francisco, United StatesFounded 2019astrinbio.com

Astrin Biosciences is pioneering a novel diagnostic platform designed to detect cancer in its earliest stages by monitoring real-time biological activity. The company's mission is to shift cancer diagnosis from reactive to proactive, enabling earlier intervention and better survival rates. While still in the development phase, their technology holds significant promise for improving screening paradigms across multiple cancer types. Astrin is positioned as a private, pre-revenue company focused on advancing its platform through research and development.

Founded

2019

Focus

OncologyImmunology

AI Company Overview

Technology Platform

A proprietary diagnostic platform designed to detect cancer at its earliest stage by analyzing real-time biological activity and signals within the body, moving beyond static biomarkers.

Funding History

Total raised: $3.4M

Seed$3MY CombinatorSep 15, 2022

Grant$400KNCIMay 23, 2022

Opportunities

The global market for early cancer detection is massive and underserved.

Success would position Astrin to address high-mortality cancers with poor early detection rates, such as pancreatic and ovarian cancer, and could lead to a platform applicable across numerous oncology indications.

Risk Factors

Key risks include the high technical challenge of validating a novel detection paradigm, the substantial cost and complexity of clinical trials needed to prove clinical utility, intense competition from well-funded rivals, and the uncertain regulatory and reimbursement pathway for groundbreaking diagnostics.

Competitive Landscape

Astrin competes in the multi-cancer early detection (MCED) space against companies like GRAIL (Illumina) and Freenome. Its proposed differentiation lies in analyzing real-time biological activity, a different approach than the prevailing focus on static genomic and epigenomic biomarkers like cell-free DNA methylation.